Cat. No. 1093
Chemical Name: 5-methyl-1-phenyl-2(1H)-pyridinone
Biological ActivityAntifibrotic agent, effective in models of pulmonary and lung fibrosis. Inhibits collagen production and fibroblast proliferation. Regulates cytokine levels following oral administration in vivo. Potent scavenger of free radicals and inhibitor of lipid peroxidation.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Mei et al (2005) Protection of pirfenidone against an early phase of oleic acid-induced acute lung injury in rats. J.Pharmacol.Exp.Ther. 313 379. PMID: 15608079.
Oku et al (2002) Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock. Eur.J.Pharmacol. 446 167. PMID: 12098599.
Iyer et al (1999) Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J.Pharmacol.Exp.Ther. 289 211. PMID: 10087006.
Kehrer and Margolin (1997) Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol.Lett. 90 125. PMID: 9067480.
If you know of a relevant reference for Pirfenidone please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Pirfenidone from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Pirfenidone, supplier, Antifibrotic, agent, regulates, cytokine, levels, vivo, TNF-α, TNF-alpha, Interleukins, Tumor, Necrosis, Factor-α, Factor-alpha, Cytokines, Cytokine, NF-κB, NF-kappaB, Signaling, Signalling, esbriet, Tocris Bioscience, Cytokine products
Find multiple products by catalog number
New Products in this Area
Receptor for advanced glycation end products (RAGE) antagonistCP 424174
Inhibitor of IL-1β post-translational processing; indirectly inhibits NLRP3IT 901
NF-κB c-Rel subunit inhibitor
June 14 - 17, 2017
Boston, MA, USA